Clinical trial
HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol
NCT00000799 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00000799 |
|---|---|
| Title | HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol |
| Official title | HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Gilead Sciences Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Cytomegalovirus Retinitis, HIV Infections |
| Intervention type | Drug |
| Interventions | Cidofovir, Probenecid |
| Enrollment | 100 |
| Completion | Apr 1, 1996 |
| First posted | Aug 31, 2001 |
| Last update posted | Nov 1, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: